Molecular therapy for aging-associated diseases and Lifespan extension: Rosuvastatin, an anti-dyslipidemic drug used to treat lower cholesterol levels and cardiovascular disease,, increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 14/November/2018, 11.48 pm

Astrocyte-derived neurotrophic factor comes to the rescue of Diabetes Mellitus: MANF (Mesencephalic astrocyte-derived neurotrophic factor) augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 14/October/2018, 3.38 pm
November 14, 2018
A sweet way to treat Metastatic cancers: Xylobiose, a disaccharide of xylose, increases the expression of tumor/metastatic suppressors KIBRA and GAS5, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up-regulation of its target gene, 14/November/2018, 11.58 pm
November 14, 2018
Show all

Introduction: What they say

A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, New South Wales 2052, Australia shows that “A conserved NAD+ binding pocket that regulates protein-protein interactions during aging.” This research paper was published, in the 24 March 2017 issue of the journal “Science [One of the best research journals in Science with an I.F of 34+], by Prof. David A. Sinclair, Jun Li and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Molecular therapy for aging-associated diseases and Lifespan extension: Rosuvastatin, an anti-dyslipidemic drug used to treat lower cholesterol levels and cardiovascular disease,, increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene


What is known?

Prof. David A. Sinclair’s research team has recently shown that: (a) increased levels of NAD+ (found in non-aged tissues) inhibits the interaction the between DBC1 (deleted in breast cancer 1) and PARP1 [poly(adenosine diphosphate–ribose) polymerase]; and promotes DNA repair; (b) decreased levels of NAD+ (found in aged tissues) promotes the interaction between DBC1 and PARP1 and inhibits DNA repair; (c) aged cells/tissues that are low in NAD+ are radiation-sensitive, cancer-prone and prone to accelerated ageing; and (d) ageing-associated diseases can be reversed by increasing the concentration of NAD+ in ageing tissues, suggesting that ageing-associated diseases, in part, can be reversed by NAD+ supplementation in older animals.


From research findings to therapeutic opportunity:

This study suggests, for the first time, a small molecule-based therapy for both aging-associated diseases; and life-span extension. Rosuvastatin, by increasing the expression of its target gene, it may increase the levels of NAMPT and NMN/NAD+. Thereby, it may: (1) increase plasma NMN levels and tissue NAD+ availability; (2) inhibit the interaction between DBC1 and PARP1; (3) augment PARP1’s DNA repair activity; (4) protect against radiation; (5) protect against cancer; and (6) prevent age-associated gene expression pattern and accelerated ageing. Thus, pharmacological formulations encompassing “Rosuvastatin or its analogs, either alone or in combination with other nutritional compounds,” may be used to suppress age-associated overall physiological decline and improve health/lifespan.[easy_payment currency=”USD”]

Figure1. Rosuvastatin may act as an anti-aging and a longevity-promoting compound.  Rosuvastatin, by increasing NAD+ levels, may suppress aging-associated overall physiological decline, aging-associated diseases and improve health/lifespan

Figure 2. The chemical structure of Rosuvastatin


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How Rosuvastatin increases the levels of NMN/NAD to inhibit interaction between DBC1 and PARP1 and to promote DNA repair activity

Amount: $300#

* Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Citation: Boominathan, L., Molecular therapy for aging-associated diseases and Lifespan extension: Rosuvastatin, an anti-dyslipidemic drug used to treat lower cholesterol levels and cardiovascular disease,, increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down-regulation of its target gene, 14/November/2018, 11.47 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite us, kindly drop us a line

Comments are closed.